Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVPD regimen for relapsed/refractory multiple myeloma resistant to bortezomib and/or lenalidomide
ChiCTR2300078643Phase 4Recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixazomib, venetoclax, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by The Second Hospital of Hebei Medical University. Primary endpoints: Objective response rate and Progression-free survival. Started Dec 2023; status: recruiting.
02
Drugs
ixazomibvenetoclaxpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2300078643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078643.